Coupled with the understanding of the importance of preservation of microvascular bed and the inability to progress further on the available systemic<unk> , there is renewed interest in local drug delivery to achieve higher than usual local drug concentrations.
The most common IC<unk> es are vasodilators, with the most popular being nitroglycerine. There is somewhat frequent use of adenosine and nicardipine, though, most of the experience is mainly on adenosine. Use of verapamil and diltiazem are declining due to the availability of nicardipine.
Despite the lack of randomized trials, the use of IC<unk> es in niche situations, such as prevention and treatment of no-reflow, may prove to be life saving.
The evidence on the use of<unk>  glycoprotein inhibitors is sparse. Until more robust data becomes available, regular use of this class of medications is not recommended.
There has been several studies looking at<unk>  thrombolytics. However there is no evidence to suggest that they are superior to current therapy.
Future studies are expected to address some of the issues in this arena.
Intracoronary pharmacotherapy
Intervention in left main coronary artery disease
Hybrid coronary revascularization
AV nodal ablation
Ventricular tachycardia ablation
Cardiac resynchronization therapy procedure
Cardiac resynchronization therapy
Percutaneous coronary intervention